Clinicopathological characteristics and outcomes of ROS1‐rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements. Issue 4 (July 2015)

• Record Type: Journal Article
• Authors: Wu, Shafei; Wang, Jinghui; Zhou, Lijuan; Su, Dan; Liu, Yuanyuan; Liang, Xiaolong; Zhang, Shucai; Zeng, Xuan
• Is Part Of: Thoracic cancer. Volume 6:Issue 4(2015)
• Page Start: 413
• Page End: 420
• Publication Date: 2015-07
• Subjects: Chest -- Cancer -- Periodicals; Chest -- Cancer -- Treatment -- Periodicals; Chest -- Surgery -- Periodicals; 616.99494005
• DOI: 10.1111/1759-7714.12191
• Languages: English
• ISSNs: 1759-7706

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="tca12191-sec-0001" sec-type="section"> <title>Background</title> <p>c‐ros oncogene 1 (<italic>ROS1</italic>) rearrangement presents one of the newest molecular targets in non‐small cell lung cancer (NSCLC). <italic>ROS1</italic> rearrangement is predominantly found in adenocarcinoma cases and is exclusive to other oncogenes, such as epidermal growth factor receptor (<italic>EGFR</italic>), Kirsten rat sarcoma viral oncogene homolog (<italic>KRAS</italic>), and anaplastic lymphoma kinase (<italic>ALK</italic>). The aim of this study was to investigate the clinicopathological characteristics and outcomes of <italic>ROS1‐</italic>rearranged patients with lung adenocarcinoma without <italic>EGFR</italic> and <italic>KRAS</italic> mutations and <italic>ALK</italic> rearrangements.</p> </sec> <sec id="tca12191-sec-0002" sec-type="section"> <title>Methods</title> <p>Wild‐type <italic>EGFR</italic>/<italic>KRAS</italic>/<italic>ALK</italic> patients with lung adenocarcinoma were selected from Beijing Chest Hospital. Specimens were conducted in tissue microarrays. <italic>ROS1</italic> rearrangement was screened using fluorescence in situ hybridization.</p> </sec> <sec id="tca12191-sec-0003" sec-type="section"> <title>Results</title> <p>Our study included 127 patients with lung adenocarcinoma without <italic>EGFR</italic> and <italic>KRAS</italic> mutations and <italic>ALK</italic> rearrangements. <italic>ROS1</italic> rearrangement was detected in five (3.9%) of the 127 patients. Compared with <italic>ROS1</italic>‐negative patients, the positive rate of <italic>ROS1</italic> in female patients was significantly higher than in male patients (9.8% vs. 0.0%, <italic>P</italic> = 0.009). There were no differences in age, smoking status, stage or histological subtype between <italic>ROS1</italic>‐positive and <italic>ROS1</italic>‐negative patients. No significant difference in survival was detected between the <italic>ROS1</italic>‐positive and <italic>ROS1</italic>‐negative patients.</p> </sec> <sec id="tca12191-sec-0004" sec-type="section"> <title>Conclusions</title> <p> <italic>ROS1</italic> rearrangement is a rare subset of lung adenocarcinoma. In 127 patients with lung adenocarcinoma, 3.9% of <italic>ROS1</italic>‐positive patients with wild‐type <italic>EGFR</italic>/<italic>KRAS</italic>/<italic>ALK</italic> were found.</p> </sec> </abstract>